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INTRODUCTION
Preeclampsia, characterized by hypertension, proteinuria
or edema after the 20th week of gestation, is a heterogeneous
disorder which complicates 5-7% of all pregnancies and
remains a leading cause of maternal and fetal mortality (1).
Although the etiology is unclear, a strong genetic component
has been suggested because it is more common in blood rel-
atives of affected women (2) and in pregnancies fathered by
sons of preeclamptic women (3). The renin-angiotensin (RA)
system has been implicated to play a role in the pathophysi-
ology of preeclampsia. Data in support of this include 1) lower
levels of all circulating components of the RA system, and
activation of cellular and tissue RA components at the same
time, and 2) pregnancy-associated blunting of angiotensin II
(AII) pressor responsiveness which is owing to excessive upreg-
ulation of AII receptors in a variety of tissues (4, 5). However,
why some women are prone to and others are protected from
this disease is unknown. It has been suggested that genetic
factors such as gene polymorphisms of the RA system may
play an important role in the regulation of blood pressure
(BP) in preeclampsia. 
Ward et al. (6) and Arngrimsson et al. (7) found that a mo-
lecular variant of angiotensinogen (M235T) in Caucasians and
Japanese was significantly associated with preeclampsia and
in part influenced the development of preeclampsia. Recently
in Korean women, familial tendency of hypertension and
angiotensinogen AA genotype showed an association with
high BP in hypertensive disorder in pregnancy (8). On the
contrary, Guo et al. (9) found that there was no significant
association of the M235T allele of angiotensinogen with
preeclampsia/eclampsia in a population case-control study
among Australians and Chinese. An insertion/deletion poly-
morphism in the angiotensin-converting enzyme (ACE) gene
is associated with serum ACE activities, with the DD geno-
type having the highest activity (10). Although the DD type
of ACE gene polymorphism is suggested to be a circulatory
maladaptation in hypertension during pregnancy, there was
no effect of ACE gene polymorphism on pregnancy outcome,
the incidence of pregnancy-induced hypertension (PIH) or
changes in BP during pregnancy (11). Differences in ethnic
background probably contribute to variable gene frequencies
of the RA system, which may manifest as differences in the
incidence of these disorders in population groups (12, 13).
In the present study, we questioned whether ACE and angio-
tensinogen gene polymorphisms might be associated with
preeclampsia in Korean women.
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Association of Angiotensin-Converting Enzyme and Angiotensinogen
Gene Polymorphisms with Preeclampsia 
We tested the hypothesis that angiotensin-converting enzyme (ACE) and angioten-
sinogen gene polymorphism influence the incidence, development and outcome of
preeclampsia. Subjects were recruited from 90 Korean patients with preeclampsia
during pregnancy and 98 age-matched controls. After isolation of DNA, polymerase
chain reactions (PCR) were carried out to detect polymorphism of the ACE and
angiotensinogen. M235T and T174M genotypes of angiotensinogen were determined
by digestion with restriction enzyme endonuclease Tth 111-I and NCo I, respectively.
The frequency of DD genotype was significantly greater in preeclampsia (0.36) than
in controls (0.14) (p<0.05). The frequency of D allele was 0.55 in preeclampsia and
0.40 in controls (p<0.05). There were no differences in the onset of preeclampsia
and pregnancy outcomes according to the ACE genotypes. There was no difference
in the frequency of a allele of angiotensinogen M235T between the groups (0.79:
0.78 in preeclampsia : controls). The frequency of T allele of angiotensinogen T174M
gene was slightly increased, but not significantly, in preeclampsia (0.11) than in con-
trols (0.07). In a multivariate analysis, only ACE genotype was associated with the
development of preeclampsia ( =0.27, p=0.05). In conclusion, a molecular variant
of ACE, but not angiotensinogen, gene is associated with preeclampsia in Korean
women. 
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MATERIALS AND METHODS
Subjects and protocol
Ninety consecutive patients with preeclampsia were recruit-
ed from the Hypertension Clinic at the Samsung Cheil Hos-
pital, Sungkyunkwan University School of Medicine between
May 1996 and January 2000. The system advocated by the
U.S. National Institute of Health working group on hyper-
tension in pregnancy was used for the classification of hyper-
tension during pregnancy (14). The definition used for pre-
eclampsia, commonly referred to as severe preeclampsia, is
based on hypertension (BP greater than systolic BP 140
mmHg or diastolic BP 90 mmHg) and more than 1 g/L (or
2+ dipstick) of proteinuria in random urine determinations
with or without edema after the 20th week of pregnancy.
Cases of mild preeclampsia (less than +1 proteinuria by dip-
stick) were not included in this study. To exclude underly-
ing renal disease, we confirmed the absence of proteinuria
more than four weeks after delivery. Other exclusion criteria
included overt cardiac disease, serum creatinine >150  mol/L
or the presence of other systemic disease. Ninety-eight nor-
motensive volunteers (age-matched control) were randomly
recruited from the Obstetrics clinic at the Samsung Cheil
Hospital intermittently between 1996 and 2000. The Ethical
Committee of Samsung Cheil Hospital approved the proto-
col and informed consent was obtained from all participants.
Laboratory methods 
DNA was isolated from peripheral leukocytes using com-
mercially available kit (Takara Co., Ltd., Japan). All poly-
merase chain reactions to detect polymorphism of the ACE
and angiotensinogen (M235T and T174M) genes were car-
ried out with 100 ng of genomic DNA as a template, using
a DNA Thermal Cycler PJ2000 (Perkin Elmer Co., Norwalk,
CT, U.S.A.). To identify I/D polymorphism of the ACE gene,
the protocol of Rigat et al. (15) was used. Because of some
reports of false negative results for the insertion, nested PCR
was performed in all cases of II genotype (16). The PCR prod-
ucts of two alleles of 490 and 190 bp were electrophoresed
in 2% agarose gels, and visualized by ethidium bromide stain-
ing. The protocols of genotyping of angiotensinogen, T174M
an M235T, were taken from those of Morise et al. (17) and
Bennett et al. (18), respectively. To identify the genotype of
angiotensinogen (M235T), PCR products were digested with
restriction endonuclease Tth 111-1, electrophoresed in 2%
agarose gels, and visualized by ethidium bromide staining.
The genotype of angiotensinogen (T174M) was determined
by digestion of 303 bp amplified product with an exiting
NCo I cutting site and electrophoresed in 2.5% agarose gel.
Analytical Techniques 
To determine whether the proportions of the genotype ob-
served in our data were those to be expected in a random mat-
ing equilibrium population, they were explored using the  2
method under the Hardy-Weinberg law. The clinical charac-
teristics of the two or three groups were expressed as mean±
SD and were compared by using the Student’s t-test or ANO-
VA. Allele frequencies were deducted from genotype frequen-
cies, and differences in the distribution of genotypes between
preeclampsia and control group were determined by the chi-
square test. p value <0.05 was considered to be significant.
RESULTS
There were no differences in maternal age, body weight and
body mass index before pregnancy between preeclampsia and
control. The gestational age at birth and birth weight were
significantly lower in preeclampsia (Table 1). The peak sys-
tolic/diastolic BP during pregnancy was 155±17/100±14
mmHg in the preeclampsia and 118±11/75±8 mmHg in
the control (both, p<0.01). The genotypic distribution of the
ACE and angiotensinogen gene was compatible with the pop-
ulation in the Hardy-Weinberg equilibrium. The frequency
of DD genotype was significantly greater in preeclampsia
(0.36) than in controls (0.14) (p<0.05). The frequency of D
allele was 0.55 in preeclampsia, and 0.40 in controls (p<0.05)





Age (yr) 30.2±4.5 30.9±4.7
*Body weight, kg 54.1±7.4 53.1±5.8
*Body mass index, kg/m
2 21.8±3.4 22.0±2.8
Primigravida, % 69 67
Family history of hypertension, % 41 26
� Systolic blood pressure, mmHg 155±17 118±11
�
� Diastolic blood pressure, mmHg 100±47 5 ±8
�
� Mean blood pressure, mmHg 119±13 89±9
�
Gestational age at birth, weeks 36.2±3.5 39.7±1.0
�
Weight gain, kg 16.2±5.2 14.6±3.2
Fetal weight, kg 2.5±0.7 3.3±0.5
�
Table 1. Demographic data
*, Body weight and Body mass index before pregnancy. 
� , peak blood
pressure measured during pregnancy. 
�
, p<0.001; ns, not significant.
Results are mean±SD.
ACE, angiotensin-converting enzyme; q
d, frequency of D allele. *, p<0.05
(vs. control in ACE).
ACE
Genotype DD ID II q
d
Preeclampsia* 36 38 26 0.55
Control 14 52 34 0.40
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ence in the onset of proteinuria according to ACE genotypes:
33.1 weeks in DD and 34.7 weeks in II (p>0.05). The onset
of hypertension (more than 140/90 mmHg) in preeclampsia
was 33.7 in DD, 35.3 in ID, and 33.7 weeks in II (p>0.05)
(Table 3). In preeclampsia, there was no significant associa-
tion of pregnancy outcome according to the ACE genotypes:
no difference in the gestational age at birth and the birth
weight among the three genotypes (Table 3). The number of
intrauterine fetal death was 2 in DD, 3 in ID, and 2 II accord-
ing to the ACE genotype in patients with preeclampsia (p>
0.05). In a multivariate analysis including age, prepregnancy
body weight and body mass index, weight gain, primigravida,
and genotypes of ACE and angiotensinogen, the ACE geno-
type was the only marker associated with the development
of preeclampsia ( =0.27, p=0.05).
We could not find significant association of the molecular
variant of angiotensinogen (M235T) in preeclampsia and con-
trols; aa:Aa was 0.56:0.42 in preeclampsia and aa:Aa:AA was
0.61:0.33:0.06 in controls. There were no differences in the
frequency of a allele of angiotensinogen M235T in the two
groups (0.79:0.78 in preeclampsia : controls, respectively p>
0.05) (Table 4). The genotype of angiotensinogen T174M
showed CC:CT:TT was 0.85:0.14:0.01 in controls (p>0.05).
The frequency of T allele was slightly increased, but not signifi-
cantly, in preeclampsia (0.11) than controls (0.07) (p>0.05).
DISCUSSION
ACE and angiotensinogen are key components of the RA
system, which is a powerful regulatory system with a major
influence on salt and water metabolism and blood pressure.
In this study, we found that ACE gene polymorphism has a
significant impact on the development of preeclampsia with-
out affecting the outcome of pregnancy in Korean women.
To our knowledge, this is the first positive result on the asso-
ciation of preeclampsia and ACE gene polymorphism. 
There are conflicting results on the relationship of ACE
activities with pregnancy-induced hypertension or preeclamp-
sia and chronic hypertension superimposed on pregnancy-
induced hypertension (19, 20). Plasma ACE level has been
associated with the insertion/deletion (I/D) polymorphism
in intron 16 of the ACE gene (15). The ACE I/D polymor-
phism accounted for half of total phenotypic variance of serum
ACE, contributing much to the variability of ACE level (15).
The DD genotype is associated with higher tissue and plasma
ACE levels, whereas the II genotype is associated with lower
levels and the ID genotype with intermediate levels. The rea-
son for the higher ACE levels in the D allele has been assumed
that the I allele has a sequence similar to a silencer sequence
(21). In other studies, however, ACE activity and ACE I/D
polymorphism were not found to be associated with preeclam-
psia (22-24). Rasmussen et al. (25) found that serum ACE
activities were lower in patients with preeclampsia than
women with normal pregnancy, and proposed that this phe-
nomenon reflects a decreased placental synthesis of ACE in
preeclampsia. In the present study, we did not measure ACE
activities.
Data from animal studies have shown that the hypertension
gene is close to the ACE gene locus (26, 27). Based on this,
it could be postulated that the D allele of ACE gene is more
common in preeclampsia than normotensive controls. Our
data here support this notion as with other study (28). The
frequency of ACE gene polymorphism in the general popu-
lation of Korea is that DD:ID:II was 0.16:0.49:0.35, respec-
tively, and D:I allele frequency was 0.41:0.59 (12). The fre-
quency of the DD genotype in patients with preeclampsia
was about 2.5 times higher compared to general population
and normotensive women during pregnancy in Korea. How-
ever, there were other studies showing no association or oppo-
site result on the ACE genotype and preeclampsia (29, 30).
In a relative small study in Korean women, the I allele of the
ACE gene was associated with preeclampsia (30). In each ACE
genotype, there was no significant association between the
genotypes and the onset of proteinuria and hypertension in
our study. Also we could not find any association of pregnancy
outcome with ACE genotype. This is in agreement with that
of Tamura et al. (11). It is unclear to explain this mismatched
ACE genetic influence on the incidence of preeclampsia with-
out affecting on the outcome of pregnancy, but the multifac-
torial pathogenesis on the development and complication in
preeclampsia and also physician’s intervention may contribute
to the pregnancy outcome. One interesting study on the ACE
genetic polymorphism and obstetric complication showed
that the D genotype had higher recurrence of an adverse preg-
AGT, angiotensinogen; q
t, frequency of T allele; q
a, frequency of a allele.
All, p>0.05.
AGT M235T AGT T174M
Genotype aa Aa AA q
a CC CT TT q
t
Preeclampsia 58 42 0.79 79 21 0 0.11
Control 61 33 6 0.78 85 14 1 0.07
Table 4. Molecular variants of Angiotensinogen (M235T and
T174M) genes (%)
D, deletion; I, insertion; IFUD, intrauterine fetal death. All, p>0.05.
DD ID II
Number 33 34 23
Age (yr) 30.0±4.2 30.4±4.9 29.6±3.3
Gestational age at birth 36.3±3.8 36.9±2.9 35.9±3.6
Birth weight, g 2,357±810 2,653±662 2,257±762
IUFD, number 2 3 2
Onset of proteinuria (wk) 34.7±3.9 35.5±3.3 33.1±7.4
Onset of hypertension (wk) 33.7±4.1 35.3±3.2 33.7±4.1
Table 3. The onset of proteinuria and hypertension and pregnan-
cy outcome according to ACE gene polymorphism in patients
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nancy outcome in women with a history of preeclampsia by
affecting uteroplacental and umbilical flows (28).
Jeunemaitre et al. (31) have proposed that increased con-
centration of plasma or tissue angiotensinogen in individuals
carrying variants of angiotensinogen, such as M235T, could
lead to increased baseline or reactive production of angiotensin
II, the final effector hormone of the RA system. This long-
standing over-stimulation could activate autoregulatory mech-
anisms, resulting in increased vascular tone and hypertrophy.
This could trigger an imbalance between vasodilatory and
vasoconstrictory mechanisms: increased sensitivity to angio-
tensin II concurrent with the reduced plasma levels of most
components of this system (32). At first in 1993, Ward et al.
(6) and Arngrimsson et al. (7) observed a significant associa-
tion of preeclampsia with a molecular variant of angiotensino-
gen, M235T, in Caucasians and Japanese, and this higher
plasma concentration of angiotensinogen observed in carriers
of the M235T variants may cause a greater circulatory mal-
adaptation of the RA system during pregnancy. In contrast,
Guo et al. (9) found that there was no significant difference
in the genotypes frequencies of the M235T allele between
preeclampsia/eclampsia cases and controls in Australian and
Chinese populations, but this may be attributable to the cri-
teria used to diagnose preeclampsia. In our results, the fre-
quencies of the M235T allele were very similar to those of
preeclampsia/eclampsia and control groups in Chinese subjects.
Because different diagnostic criteria for preeclampsia may
influence experimental and control groups, we recruited true
severe preeclampsia: pregnancy-specific complication with
hypertension and more than 1 g/L of proteinuria with/with-
out edema, which occurred later than the 20th weeks of preg-
nancy. Patients who were hypertensive without proteinuria
were classified as pregnancy-induced hypertension. Racial
differences in an association study could lead to spurious dif-
ferences in allele frequencies. Therefore, only Korean women
were recruited in our study.
Preeclampsia is a multisystem and multifactorial compli-
cation of pregnancy. The precise cause of preeclampsia has not
been determined, but maladaptation to the RA system may
play a role. The products of genes involving the components
of this system may be potential candidates for preeclampsia
and hypertension related to pregnancy. In conclusion, our
study showed that I/D polymorphism of the ACE gene, rather
than angiotensinogen gene, T174M and M235T, is associated
with incidence, but not with the outcome, of preeclampsia
in Korean women. Different gene polymorphism of the com-
ponents of the RA system may contribute to the heterogeneity
of preeclampsia in different ethnic groups. In Korean woman,
the molecular variant of the ACE gene seems to be important.
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